Compare · BNTX vs REPL
BNTX vs REPL
Side-by-side comparison of BioNTech SE (BNTX) and Replimune Group Inc. (REPL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and REPL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $28.65B, about 19.2x REPL ($1.49B).
- Over the past year, BNTX is up 8.8% and REPL is up 178.7% - REPL leads by 169.8 points.
- REPL has been more active in the news (22 items in the past 4 weeks vs 7 for BNTX).
- Both have 25 recent analyst ratings on file.
- Company
- BioNTech SE
- Replimune Group Inc.
- Price
- -
- -
- Market cap
- $28.65B
- $1.49B
- 1M return
- +25.06%
- +82.98%
- 1Y return
- +8.83%
- +178.66%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2018
- News (4w)
- 7
- 22
- Recent ratings
- 25
- 25
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Replimune Group Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
- Amendment: SEC Form 20-F/A filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
Latest REPL
- Director Astley-Sparke Philip gifted 50,000 shares, decreasing direct ownership by 4% to 1,362,414 units (SEC Form 4)
- Chief Financial Officer Hill Emily Luisa sold $132,176 worth of shares (9,256 units at $14.28), decreasing direct ownership by 4% to 215,852 units (SEC Form 4) to satisfy withholding tax
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form S-3ASR filed by Replimune Group Inc.
- Replimune Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
- Chief Executive Officer Patel Sushil sold $510,253 worth of shares (39,341 units at $12.97), decreasing direct ownership by 5% to 708,151 units (SEC Form 4) to cover taxes
- Chief Financial Officer Hill Emily Luisa sold $148,481 worth of shares (11,448 units at $12.97), decreasing direct ownership by 5% to 225,108 units (SEC Form 4) (for tax liability)
- Chief Medical Officer Xynos Konstantinos sold $148,468 worth of shares (11,447 units at $12.97), decreasing direct ownership by 5% to 224,215 units (SEC Form 4) (tax liability)
- Chief Accounting Officer Schwendenman Andrew sold $98,987 worth of shares (7,632 units at $12.97), decreasing direct ownership by 7% to 99,425 units (SEC Form 4) (withholding tax)